Meloxicam

CHEMBL599 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
351.4 g/mol
LogP
3.0
Phase
4

An NSAID that selectively inhibits COX-2 to reduce pain and inflammation from osteoarthritis, rheumatoid arthritis, and juvenile arthritis, with a somewhat lower risk of gastrointestinal side effects compared to non-selective NSAIDs. It is taken once daily due to its long half-life.

分子量

351.4000 g/mol

LogP

3.00

TPSA

136.00 Ų

リピンスキーの五則

適合

治療領域

作用機序

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1

InChI

InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)

Molecular Formula

C14H13N3O4S2

HBD / HBA

2 / 7

回転可能結合数

2

重原子数

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

An NSAID that selectively inhibits COX-2 to reduce pain and inflammation from osteoarthritis, rheumatoid arthritis, and juvenile arthritis, with a somewhat lower risk of gastrointestinal side effects compared to non-selective NSAIDs. It is taken once daily due to its long half-life.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Meloxicam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL599. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 54677470. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.